文献速递乳腺癌放疗姑息放疗与转移瘤

Sacituzumab Govitecan联合放疗的安全性与疗效:法国ATTENTION多中心回顾性研究

Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-12

结果显示同期SG放疗未出现≥3级毒性,1-2级放疗相关毒性17例(27%),中位总生存12.9个月(95%CI,7.97-17.77),提示同期治疗可行且疗效可期。

要点

  • 1-2级放疗相关毒性17例(27%),含3例皮炎、4例食管炎、1例脑坏死。
  • 中位随访7.9个月,中位总生存12.9个月(95%CI,7.97-17.77)。

核心结论

  • 在乳腺癌患者中,SG与放疗同期给药未观察到≥3级毒性, feasibility与疗效均较有前景,但尚需前瞻性试验确认。

研究设计与样本

  • ATTENTION为6家法国机构开展的回顾性多中心研究,纳入2021年9月至2025年1月接受放疗与SG治疗的乳腺癌患者。
  • 同期治疗定义为SG给药前后4天内实施放疗;数据经在线问卷收集、病历复核及当地伦理委员会方案验证。

主要发现

  • 63个病灶中同期治疗37个(中位间隔3天),序贯治疗26个(中位间隔10天)。
  • 放疗相关1-2级毒性17例(27%),包括3例皮炎、4例食管炎和1例脑坏死;同期SG未出现≥3级毒性。
  • 总体缓解率为完全缓解25%、部分缓解80%;中位总生存12.9个月(95%CI,7.97-17.77),中位随访7.9个月(1.7-35.4)。

关键数值与推荐

  • 安全性与毒性按CTCAE v5.0分级评估,疗效按RECIST v1.1和/或临床症状改善评估,评估时间为放疗后4-12周。
  • 放疗目的:姑息/对症占57%,针对进展占43%;靶区以骨(49%)和脑(32%)为主。
  • 放疗技术:3D适形放疗52%、立体定向体部放疗40%、调强放疗8%。
  • 亚型分布:HER2-/HR- 30%、HER2-/HR+ 27%、HER2-low/HR+ 24%、HER2-low/HR- 18%、HER2+ 2%。
  • SG治疗线数:二线16%,≥四线54%。

临床怎么用

  • 对接受SG治疗的乳腺癌患者,可考虑对骨或脑转移灶行同期或序贯放疗,但需密切监测皮炎、食管炎及脑坏死等毒性。
  • 目前证据来自回顾性研究,同期治疗的决策应个体化,并建议在前瞻性试验框架内进一步验证。

局限性

  • 同期与序贯治疗的定义基于给药前后4天的时间窗,各组样本量较小,结论需前瞻性试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Based on the results of the ASCENT trial, sacituzumab govitecan (SG) has been approved for the treatment of breast cancer. With the expanding indications across multiple cancers, data on its combination with radiation therapy (RT) are needed. METHODS AND MATERIALS: ATTENTION is a retrospective multicenter study from 6 French institutions. Eligibility criteria included patients with breast cancer who received RT and SG between September 2021 and January 2025. Concomitant treatment was defined as RT administered within 4 days before or after SG administration. Data were collected through an online questionnaire and centralized after medical record review, and protocol validation by the local ethics committee. The primary endpoint was safety profiles according to the Common Terminology Criteria for Adverse Events, version 5.0. Secondary endpoints included treatment response, evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1 criteria and/or clinical symptom improvement. Assessment was performed 4-12 weeks after RT. RESULTS: Fifty-five patients (63 lesions) were included. The median age was 56 years (37-82). SG and RT were administered concurrently in 37 lesions (median, 3 days), sequentially in 26 lesions (median, 10 days). Subtypes included human epidermal growth factor receptor 2 (HER2)-/hormone receptors (HR)- (30%), HER2-/HR+ (27%), HER2-low/HR+ (24%), HER2-low/HR- (18%), and HER2+ (2%). SG was given as second-line in 16%, and ≥ fourth-line in 54%. RT was symptomatic in 57% and for progression in 43%, mostly targeting bone (49%) and brain (32%), using 3D conformal RT (52%), stereotactic body RT (40%), or intensity modulated RT (8%). With a median follow-up of 7.9 months (1.7-35.4), RT-related toxicities of grade 1-2 occurred in 17 cases (27%), (3 dermatitis, 4 esophagitis, and 1 brain radionecrosis). No grade ≥ 3 toxicity occurred with concomitant SG. The overall response rate was 25% complete and 80% partial responses. Median overall survival was 12.9 months (95% CI, 7.97-17.77). CONCLUSIONS: ATTENTION is the largest study that confirms the feasibility and promising efficacy of concurrent treatment, pending confirmation in prospective trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Alati A, Debbi K, Scher N, et al. Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 41391611. doi:10.1016/j.ijrobp.2025.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。